Stockscreener 앱 받기
8.92
1.87%
-0.17
시간 외 거래:
8.93
0.010
+0.11%
Arvinas Inc 주식(ARVN)의 최신 뉴스
Arvinas Q1 earnings call highlights - MSN
Arvinas (ARVN) CEO reports small automatic share sale for RSU tax withholding - Stock Titan
(ARVN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
ARVN Stock Price, Quote & Chart | ARVINAS INC (NASDAQ:ARVN) - ChartMill
Arvinas (NASDAQ: ARVN) insider sells shares; RSU settlement reported - Stock Titan
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight - GlobeNewswire Inc.
Arvinas Employees Give Back During Company-wide Impact Day - Sahm
Earnings call transcript: Arvinas Inc. reports Q1 2026 earnings, stock reacts - Investing.com India
Arvinas staff spend a day cooking, cleaning and crafting for patients and kids - Stock Titan
Earnings call transcript: Arvinas Inc. reports Q1 2026 earnings, stock reacts By Investing.com - Investing.com South Africa
Goldman Sachs Downgrades Arvinas (ARVN) - MSN
Arvinas (ARVN) moves 6.9% higher: Will this strength last? - MSN
These analysts increase their forecasts on Arvinas after Q1 results - MSN
Analysts Offer Insights on Healthcare Companies: SCHOTT Pharma AG & Co. KGaA (1SXP) and Arvinas Holding Company (ARVN) - The Globe and Mail
Analysts Just Published A Bright New Outlook For Arvinas, Inc.'s (NASDAQ:ARVN) - Sahm
Pfizer, Arvinas ink licensing deal with Rigel for breast cancer therapy - MSN
Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts - Moomoo
Bullish: Analysts Just Made A Noticeable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts - Yahoo Finance
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer - Yahoo Finance
HC Wainwright Comments on Arvinas' Q2 Earnings (NASDAQ:ARVN) - MarketBeat
Wedbush Maintains Arvinas(ARVN.US) With Hold Rating, Maintains Target Price $11 - Moomoo
Earnings Beat: Arvinas, Inc. (NASDAQ:ARVN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
BofA Securities Raises Price Target on Arvinas to $16 From $14 - marketscreener.com
These Analysts Increase Their Forecasts On Arvinas After Q1 Results - Sahm
Vanguard Group Inc. Sells 1,331,629 Shares of Arvinas, Inc. $ARVN - MarketBeat
Rigel Pharmaceuticals (RIGL) Is Up 20.5% After Global VEPPANU Rights Deal With Pfizer, ArvinasHas The Bull Case Changed? - Yahoo Finance
Wall Street Analysts Think Arvinas (ARVN) Could Surge 25.57%: Read This Before Placing a Bet - MSN
Randy Teel Sells 9,657 Shares of Arvinas (NASDAQ:ARVN) Stock - MarketBeat
Insider Selling: Arvinas (NASDAQ:ARVN) CAO Sells 1,919 Shares of Stock - MarketBeat
Insider Selling: Arvinas (NASDAQ:ARVN) Insider Sells 11,108 Shares of Stock - MarketBeat
Arvinas president and CEO Randy Teel sells $95,965 in stock By Investing.com - Investing.com Canada
Arvinas CSO Angela Cacace sells $95,965 in company stock By Investing.com - Investing.com India
Arvinas president and CEO Randy Teel sells $95,965 in stock - Investing.com
Arvinas CSO Angela Cacace sells $95,965 in company stock - Investing.com
Arvinas CFO Andrew Saik sells $110,692 in company shares By Investing.com - Investing.com South Africa
Arvinas CFO Andrew Saik sells $110,692 in company shares - Investing.com
Arvinas (ARVN) CFO sells 11,139 shares to cover RSU taxes - Stock Titan
Arvinas (ARVN) VP Loomis has 1,919 shares sold to cover RSU taxes - Stock Titan
Arvinas (ARVN) CSO share sale covers RSU tax withholding - Stock Titan
Arvinas (ARVN) CMO share sale covers RSU tax withholding - Stock Titan
Automatic tax sale trims Arvinas (NASDAQ: ARVN) CEO share holdings - Stock Titan
BofA raises Arvinas stock price target on Veppanu out-licensing deal By Investing.com - Investing.com South Africa
BTIG raises Arvinas stock price target on commercial partnership By Investing.com - Investing.com India
BofA raises Arvinas stock price target on Veppanu out-licensing deal - Investing.com Nigeria
Goldman Sachs Maintains Arvinas(ARVN.US) With Sell Rating, Maintains Target Price $6 - Moomoo
H.C. Wainwright Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $18 - Moomoo
ARVN Maintained by Barclays -- Price Target Raised to $20 - GuruFocus
Arvinas anticipates US ARV-102 PSP trial by end of 2026 while maintaining cash runway into second half of 2028 - MSN
0.98%
0.12%
자본화:
|
볼륨(24시간):